Claims for Patent: 5,126,375

Summary for Patent: 5,126,375

Title:	Phenethanolamine derivatives
Abstract:	Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12; Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group; R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and the physiologically acceptable salts and solvates thereof. The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients. The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.
Inventor(s):	Skidmore; Ian F. (Herts, GB2), Lunts; Lawrence H. C. (Herts, GB2), Finch; Harry (Herts, GB2), Naylor; Alan (Herts, GB2)
Assignee:	Glaxo Group Ltd. (London, GB)
Application Number:	07/619,899
Patent Claims:	1. Compounds of formula (I): ##STR33## wherein m is an integer from 2 to 8 and n is an integer from 1 to 7 with the proviso that the sum total of m+n is 4 to 12; Ar represents a phenyl group which may be unsubstituted or substituted by one or two substituents selected from halogen atoms, C.sub.1-3 alkyl groups or C.sub.1-3 alkoxy groups; and R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom or a C.sub.1-3 alkyl group with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and physiologically acceptable salts and solvates thereof. 2. Compounds according to claim 1 wherein m is 3 and n is 6; or m is 4 and n is 3,4 or 5; or m is 5 and n is 2, 3, 4 or 5; or m is 6 and n is 2 or 3. 3. Compounds according to claim 1 wherein the sum total of m+n is 7, 8, 9 or 10. 4. Compounds according to claim 1, wherein R.sup.1 and R.sup.2 which may be the same or different each represents a hydrogen atom or a methyl group. 5. Compounds according to claim 1, Ar represents an unsubstituted phenyl group or a phenyl group substituted by one substituent selected from chlorine and fluorine atoms, methoxy and methyl groups. 6. Compounds of formula (Ia): ##STR34## wherein m is an integer from 3 to 6 and n is an integer from 2 to 6 with the proviso that the sum total of m+n is 7 to 10 inclusive; and Ar is phenyl or phenyl substituted by a methyl or methoxy group or a fluorine or chlorine atom; R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom or a C.sub.1-3 alkyl group with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and physiologically acceptable salts and solvates thereof. 7. Compounds of formula (Ia) according to claim 6 wherein R.sup.1 is a hydrogen atom and R.sup.2 is a hydrogen atom or a methyl group. 8. Compounds of formula Ia according to claim 6 wherein R.sup.1 and R.sup.2 which may be the same or different is each a hydrogen atom or a methyl group, m is 4 or 5, n is 2, 3 or 4 and Ar is phenyl or phenyl substituted by a chlorine or fluorine atom or a methoxy or methyl group. 9. Compounds of formula I according to claim 1 selected from the group consisting of 4-hydroxy-.alpha..sup.1 -[[[6-(2-phenylethoxy)hexyl]amino]methyl]-1,3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[5-(4-phenylbutoxy)pentyl]amino]methyl]-1,3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[1-methyl-6-(2-phenylethoxy)hexyl]amino]methyl]-1,3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[1-methyl-5-(3-phenylpropoxy)pentyl]amino]methyl]-1,3-benzenedimethanol 4-hydroxy-.alpha..sup.1 -[[[1-methyl-5-(4-phenylbutoxy)pentyl]amino]methyl]-1,3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[1-ethyl-6-(2-phenylethoxy)hexyl]amino]methyl]-1,3-benzenedimethanol; .alpha..sup.1 -[[[1,1-dimethyl-6-(2-phenylethoxy)hexyl]amino]methyl]-4-hydroxy-1,3-benze nedimethanol; .alpha..sup.1 -[[[6-[2-(4-fluorophenyl)ethoxy)]-1methylhexyl]amino]methyl]-4-hydroxy-1,3 -benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[6-[3-(4-methoxyphenyl)propoxy]-1-methylhexyl]amino]methyl]-1,3-benzene dimethanol; 4-hydroxy-.alpha..sup.1 -[[[1-methyl-6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[6-[2-(4-methylphenyl)ethoxy]hexyl]amino]methyl]-1,3-benzenedimethanol; .alpha..sup.1 -[[[6-[2-(3-chlorophenyl)ethoxy]hexyl]amino]methyl]-4-hydroxy-1,3-benzened imethanol; 4-hydroxy-.alpha..sup.1 -[[[6-[2-(4-methoxyphenyl)ethoxy]hexyl]amino]-methyl]-1,3-benzenedimethano l; .alpha..sup.1 -[[[6-[3-(4-fluorophenyl)propoxy]-hexyl]amino]methyl]-4-hydroxy-1,3-benzen edimethanol; and the physiologically acceptable salts thereof. 10. A pharmaceutical composition comprising at least one compound of formula (I) as defined in claim 1 or a physiologically acceptable salts or solvate thereof, together with a physiologically acceptable carrier or excipient.